These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37762316)

  • 21. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
    Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
    Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.
    Jung SK; Lee MH; Lim DY; Kim JE; Singh P; Lee SY; Jeong CH; Lim TG; Chen H; Chi YI; Kundu JK; Lee NH; Lee CC; Cho YY; Bode AM; Lee KW; Dong Z
    J Biol Chem; 2014 Dec; 289(52):35839-48. PubMed ID: 25368326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
    Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
    Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
    Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
    Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer.
    Takeda M; Okamoto I; Nishimura Y; Nakagawa K
    Lung Cancer (Auckl); 2011; 2():59-67. PubMed ID: 28210119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy.
    Zhou X; Wang X; Zhu H; Gu G; Zhan Y; Liu C; Sun G
    Exp Ther Med; 2021 Jan; 21(1):9. PubMed ID: 33235618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
    Kaewjanthong P; Sooksai S; Sasano H; Hutvagner G; Bajan S; McGowan E; Boonyaratanakornkit V
    PLoS One; 2022; 17(3):e0264717. PubMed ID: 35235599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models.
    Polonio-Alcalá E; Palomeras S; Torres-Oteros D; Relat J; Planas M; Feliu L; Ciurana J; Ruiz-Martínez S; Puig T
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32438613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
    Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
    Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 33. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
    Wu W; O'Reilly MS; Langley RR; Tsan RZ; Baker CH; Bekele N; Tang XM; Onn A; Fidler IJ; Herbst RS
    Mol Cancer Ther; 2007 Oct; 6(10):2652-63. PubMed ID: 17913856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.
    Zhao L; He LR; Xi M; Cai MY; Shen JX; Li QQ; Liao YJ; Qian D; Feng ZZ; Zeng YX; Xie D; Liu MZ
    J Transl Med; 2012 Dec; 10():249. PubMed ID: 23232108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
    James R; Vishwakarma S; Chivukula IV; Basavaraj C; Melarkode R; Montero E; Nair P
    Cancer Med; 2012 Oct; 1(2):114-27. PubMed ID: 23342262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim SH; Shim HS; Cho J; Jeong JH; Kim SM; Hong YK; Sung JH; Ha SJ; Kim HR; Chang H; Kim JH; Tania C; Cho BC
    Lung Cancer; 2013 Mar; 79(3):270-5. PubMed ID: 23261229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.
    Mazorra Z; Lavastida A; Concha-Benavente F; Valdés A; Srivastava RM; García-Bates TM; Hechavarría E; González Z; González A; Lugiollo M; Cuevas I; Frómeta C; Mestre BF; Barroso MC; Crombet T; Ferris RL
    Front Pharmacol; 2017; 8():382. PubMed ID: 28674498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Near infrared fluorescence imaging of EGFR expression
    Bernhard W; El-Sayed A; Barreto K; Gonzalez C; Hill W; Parada AC; Fonge H; Geyer CR
    Oncotarget; 2018 Jan; 9(5):6213-6227. PubMed ID: 29464066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.